secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2024-09-24T23:59:59+00:00
Accession:  0001213900-24-081482
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01, 3.02, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix effects 1:40 reverse stock split; Nasdaq delisting notice resolved via new listing approval
--------------------------------------------------------------------------------

- Reverse stock split at ratio 1:40 effective Sept. 24, 2024; no fractional shares issued, cash paid in lieu.
- Nasdaq delisting notice for bid price non-compliance received Sept. 18; mooted by Sept. 19 approval of new listing application meeting $4 closing bid price.
- Issued 142,749 shares to Veru upon conversion of Series A Preferred; 6,741,820 shares to former Proteomedix holders on Series B automatic conversion.
- Issued 513,424 units (share + warrant) to Altos plus 154,027 shares on warrant exercise; all exempt from registration.
- Post-split shares outstanding: 8,307,051 total (including 2,656 unvested restricted stock).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/0001213900-24-081482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/ea0215560-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-081482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer